Shots:

• The US FDA has approved the sBLA for a new self-administration option for Xolair in patients across all approved indications in the US
• The use of the therapy across multiple indications is based on the efficacy and safety profile of Xolair in allergic asthma- CIU- and nasal polyps- supported with a clinical development program- which includes 10 P- III studies
• Xolair is the only FDA-approved biologic designed to target and block IgE. Genentech and Novartis work together to develop and co-promote Xolair in the US

  Ref: PRNewswire | Image: Novartis